Global Scans · Arthritis · Weekly Summary

• [New] Addressing the unmet rehabilitation need, such as the WHO Rehabilitation 2030 call for action, is imperative if disability is to be minimised, and equitable rehabilitation services for people with rheumatoid arthritis are required globally. PubMed Central (PMC)
• The rheumatoid arthritis competitive landscape in 2026 is defined by the convergence of maturing blockbusters, biosimilar disruption, and a wave of mechanistically novel approvals. Eureka Blog
• 31-7 million individuals will be living with rheumatoid arthritis worldwide by 2050. PubMed Central (PMC)
• An arthritis drug given with the Plan B emergency contraception pill could make it over 30% more effective. Fortune Well
• Fear of seeking healthcare support among married Chinese elderly with arthritis negatively impacts self-care and medication adherence. PubMed Central (PMC)
• The Centre for Genetics and Genomics Versus Arthritis and Research into Inflammatory Arthritis Centre protein markers in patients with rheumatoid arthritis that could predict how well people respond to a specific treatment called etanercept. Versus Arthritis
• Arthritis affects over 10 million people in the UK and Versus Arthritis estimates that it will cost the NHS £118 billion over the next decade. Stephen Timms MP
• Up to half of the UK population lives with chronic pain, a figure projected to rise with ageing populations and increasing rates of musculoskeletal conditions like arthritis. Chemistry World
• There will be 31-7 million individuals worldwide with rheumatoid arthritis, 68-7% of whom will be female. PubMed Central (PMC)
• The autoimmune diseases segment is likely to register a fastest CAGR of 14.2% from 2026 to 2034 owing to the rising prevalence of conditions such as rheumatoid arthritis psoriasis and inflammatory bowel disease which require long term biological management. Market Data Forecast
• The biologics segment is expected to exhibit a noteworthy CAGR of 9.1% from 2025 to 2033 due to its superior efficacy in halting disease progression, particularly in refractory autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Market Data Forecast

Last updated: 13 September 2026